Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the Phase 3, randomized, multicenter, ...
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated ...
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly ...
The annual Youth LEGO Build Competition, hosted by Tahlequah Area Habitat for Humanity, is returning this summer with major expansions designed to welcome more builders, more families, and greater ...
docx_url https://www.va.gov/vdl/documents/Clinical/Pri_Care_Mgmnt_Module_(PCMM)/pcmmmhtcug.docx pdf_url https://www.va.gov/vdl/documents/Clinical/Pri_Care_Mgmnt ...
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus ...
Abstract: The conventional calibration methods based on a perspective camera model are not suitable for the underground camera with two-layer glasses, which is specially designed for explosion proof ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results